Clinical Trials Browser

INDUSTRY × Interventional × Eosinophilia × Clear all

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase 2 Completed

47 enrolled 21 charts 1 FDA

Eosinophilia, Myeloproliferative Disorders